CHMP backs single Bexsero booster dose for ages 10 and up
GSK said the EU committee recommended a one-dose Meningitis B booster using Bexsero for people 10 and older who were vaccinated at least two years earlier.
SEC filing
27 stories
GSK said the EU committee recommended a one-dose Meningitis B booster using Bexsero for people 10 and older who were vaccinated at least two years earlier.
SEC filing
GSK's rectal cancer approval for dostarlimab adds a new monotherapy indication as AnaptysBio awaits a Delaware court judgment in its litigation with GSK and Tesaro.
FDA, SEC filing (3)
The agency's approval announcement names the drug and indication but does not detail trial data, dosing, or label specifics in the posted record.
FDA (3)
The company reported third-quarter 2026 results alongside an FDA submission, a trial closure expected to save up to $125 million, and $1.15 billion in cash.
SEC filing (14)
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
The company expanded its board to seven members and named Schayowitz a Class III director effective October 23, 2026.
SEC filing
GSK said mocertatug rezetecan produced a 62% confirmed response rate and 12.2-month median duration of response in the BEHOLD-1 trial, with five phase III studies now underway.
SEC filing
The licensing agreement covering the KRAS-EGFR antibody conjugate candidate took effect after antitrust clearance, triggering a $110 million upfront payment.
SEC filing
The antisense oligonucleotide, given with existing antiviral therapy, lets some adults stop all HBV treatment and keep the virus under control.
SEC filing, Drugs@FDA, FDA, FDA press release (6)
Former Sanofi CEO Hudson and Verily Health CFO Koppikar join as independent directors effective October 19, 2026, with board committee assignments and equity grants detailed in the filing.
SEC filing
The agency cleared Jemperli for a new use in locally advanced rectal cancer, saying it may let some patients skip chemotherapy, radiation, and surgery.
FDA, FDA press release, Drugs@FDA, SEC filing (5)
The company priced a 61.5 million share offering at $3.25 as Sanofi exercised an option on a first collaboration candidate and new REC-4881 and REC-1245 trial data emerged.
SEC filing (4)
The company confirmed the September 14 board appointment in a September 16 statement that included executive comments and details on Whitaker's background.
SEC filing
GSK will pay up to $750 million for a Chimagen asset expected to begin phase I trials in 2027, targeting multiple myeloma.
SEC filing
MHLW authorized a ready-to-use presentation of the shingles vaccine, replacing the two-vial format that required manual mixing.
SEC filing
HUTCHMED will get $110 million upfront as GSK takes global rights outside Greater China to the KRAS-EGFR conjugate HMPL-A830, with milestone figures stated differently across the filing.
SEC filing